Mar 21, 2023 / 05:30PM GMT
Matthew Ian Mishan - KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst
Good afternoon. I'd like to welcome everyone again to the KeyBank Life Sciences and MedTech Investor Forum. My name is Matt Mishan, I am senior MedTech analyst. I'm pleased to be joined by CooperCompanies, who is represented today by CFO and Treasurer, Brian Andrews; and EVP and COO, Dan McBride. Thank you guys for joining us. I'm going to start us off, but this will be 100% Q&A and questions can be submitted directly to me by typing into the box below the video screen and then I can relay from there.
Questions and Answers:
Matthew Ian Mishan - KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research AnalystBut I'll start off. I guess, Brian, I'm asking this question to you. It's basically as you're in San Francisco, are you talking to other CFOs about the Silicon Valley Bank issues? How do you think about direct versus tail risk at this point from that?
Brian G. Andrews - Cooper
Trustpilot
